Desmopressin in Cardiac Surgery

Università Vita-Salute San Raffaele

Overview

Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products. Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Conditions

Hemorrhage Blood Loss, Surgical Postoperative Hemorrhage

Interventions

Desmopressin (DDAVP)DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * undergoing cardiac surgery * excessive bleeding Exclusion Criteria: * age\<18 y * not signing written consent

Locations (4)

Istituto Ospedaliero Fondazione Poliambulanza

Brescia, Italy

Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia

Milan, Italy

Istituto Policlinico S.Donato

Milan, Italy

Azienda Ospedaliera Universitaria Pisana

Pisa, Italy

Outcomes

Primary Outcomes

Reduce transfusions

Secondary Outcomes

Reduced bleeding

Reduce time on mechanical ventilation

Reduced ICU and Hospital stay

Reduced mortality

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.